6PM Holdings plc - Interim Directors’ Statement

Wednesday, November 19th, 2014

On 19 November, 6PM Holdings plc published its Interim Directors’ Statement covering the period since 30 June 2014.

As the Group continued to mature, its internal focus was directed towards its core products, thereby reducing third party involvement within its solutions. The ultimate objective of the change in internal strategy is to achieve growth within revenue and pre-tax profits. The Directors reported business growth as planned, and this should enable the Company to recommend dividends at the forthcoming Annual General Meeting.

A new 3-year strategy plan has been concluded by the Board of 6PM Holdings, encompassing the changes that have been happening in 2014 to the current business strategy of the Group. During the period under review, 6PM Holdings introduced 2 new products in the NHS clinical sector – StrokePAD targeting stroke patients and ConCERT-D for dementia patients.

As iFIT remains the flagship product for the Group, the third-party software that was used within the product was replaced by an internally-developed software. iFIT2 is currently being sold to new Trusts, and existing Trusts using the iFIT version are being migrated gradually to iFIT2. This change has contributed to a slowdown in sales, although the Group reported that the sales pipeline is at its strongest ever.

As the drive to internationalise the 6PM brand continues, the Irish operation produced good results in its first year of operation. Additionally, the Group has reportedly engaged people in Macedonia, Scotland, Australia and Canada to test the receptiveness of the respective markets where 6PM could sell its current product suite.

The 10% equity holding that 6PM Group has in the US company Javali will be developed further as Javali plans to open an operation in Europe, in which 6PM intends to hold a 45% stake. 6PM was involved in developing a revenue leakage product for hospitals, which is currently being marketed in Europe. Over the coming years, this product is expected to have a significant impact on the revenues generated by the Group.

As the Executive team prepares its 2015 business plan, the focus remains on sanctioning further growth as new opportunities will be sought to enhance shareholders’ value.

Print This Page Print This Page